Scientists identify therapeutic targets to overcome radioresistance of brain cancer cells
A new drug could replace the current standard for treating radioresistance brain cancer by sensitising the cancer cells to radiotherapy.
List view / Grid view
A new drug could replace the current standard for treating radioresistance brain cancer by sensitising the cancer cells to radiotherapy.
In this article, Drug Target Review’s Izzy Wood reviews some of the latest Alzheimer's disease research, highlighting the progress that has been made toward new, more unique therapeutic strategies against Alzheimer’s.
US scientists offer a new purpose for the blood pressure drug clonidine as a treatment to reduce the affects of PTSD.
The researchers found that the protein Grb10 promotes leptin activity in the brain, opening the possibility of developing Grb10-based new approaches to treat obesity.
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
US researchers administered a therapy to Alzheimer’s patient-derived neurons in the lab, eliminating deteriorating cells, leading to positive consequences for the remaining healthy cells.
Japanese researchers found an ASD-like behavioural impairment in chicks, suggesting a molecular pathway of ASD pathogenesis.
US researchers have identified a protein that interacts and enhances the spread of neurotoxic species of tau, which is primarily found in neurons that appear abnormal in the brains of Alzheimer’s disease patients.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
US researchers, using a 3D neural tissue model, found that compounds from green tea and resveratrol could diminish Alzheimer’s amyloid plaques in lab tests, with no side effects.
The study, involving mice, found that the neurotransmitter can act as a break to dopamine.
UCL researchers have developed a possible new treatment for neurological and psychiatric diseases, that works by reducing the excitability of overactive brain cells.
A new study found that as patients age, Huntington’s disease gradually impairs the important cellular housekeeping process autophagy, which is responsible for eliminating waste from cells.
The study’s findings have important implications for better understanding the neurological basis for ASD and developing effective therapies for patients.
The molecules, called SGDGs, may lead to new ways to treat age-related neurological diseases.